×
0 0 0 0 -0.0487179487179487 -0.0958333333333333 -0.0821153846153846 -0.0422435897435898
Stock impact report

Blueprint Medicines' Highly Selective RET Inhibitor BLU-667 Shows Durable Anti-Tumor Activity in Patients with RET-Altered Cancers in Updated ARROW Trial Data Presented at ASCO 2019

Blueprint Medicines Corp (BPMC)  More Company Research Source: PR Newswire
Last blueprint medicines corp earnings: 8/1 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: blueprintmedicines.com
Impact snapshot Event time: BPMC
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Performance comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last price
VWAP
High:
Max up
High:
Low:
Max down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Opt-in for
BPMC alerts

from News Quantified
Opt-in for
BPMC alerts

from News Quantified